The University of Chicago Header Logo

Connection

Blase Polite to Middle Aged

Back to Details
This is a "connection" page, showing publications Blase Polite has written about Middle Aged.
Blase Polite
Connection Strength
0.678
Middle Aged
  1. Improving End of Life Cancer Outcomes Through Development and Implementation of a Spiritual Care Advocate Program. Am J Hosp Palliat Care. 2021 Dec; 38(12):1441-1450.
    View in: PubMed
    Score: 0.043
  2. Investigation of a multimedia, computer-based approach to improve knowledge, attitudes, self-efficacy, and receptivity to cancer clinical trials among newly diagnosed patients with diverse health literacy skills. Cancer. 2019 06 15; 125(12):2066-2075.
    View in: PubMed
    Score: 0.037
  3. Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations. Cancer. 2018 06 15; 124(12):2578-2587.
    View in: PubMed
    Score: 0.035
  4. A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med. 2018 06; 21(6):846-849.
    View in: PubMed
    Score: 0.035
  5. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911.
    View in: PubMed
    Score: 0.032
  6. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.031
  7. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
    View in: PubMed
    Score: 0.028
  8. The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Res. 2014 Sep; 34(9):5043-50.
    View in: PubMed
    Score: 0.027
  9. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90.
    View in: PubMed
    Score: 0.022
  10. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65.
    View in: PubMed
    Score: 0.018
  11. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
    View in: PubMed
    Score: 0.015
  12. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
    View in: PubMed
    Score: 0.014
  13. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
    View in: PubMed
    Score: 0.014
  14. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
    View in: PubMed
    Score: 0.013
  15. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024 01 02; 7(1):e2350903.
    View in: PubMed
    Score: 0.013
  16. Early Integrated Palliative Care Within a Surgical Oncology Clinic. JAMA Netw Open. 2023 11 01; 6(11):e2341928.
    View in: PubMed
    Score: 0.013
  17. Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
    View in: PubMed
    Score: 0.011
  18. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.011
  19. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
    View in: PubMed
    Score: 0.011
  20. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open. 2020 10 01; 3(10):e2023500.
    View in: PubMed
    Score: 0.010
  21. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2021 02; 5(1).
    View in: PubMed
    Score: 0.010
  22. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
    View in: PubMed
    Score: 0.010
  23. Gender- and Race-Based Differences in Barriers and Facilitators to Early Detection of Colon Cancer. J Womens Health (Larchmt). 2020 09; 29(9):1192-1202.
    View in: PubMed
    Score: 0.010
  24. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
    View in: PubMed
    Score: 0.010
  25. Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer. 2020 01 15; 126(2):281-292.
    View in: PubMed
    Score: 0.010
  26. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
    View in: PubMed
    Score: 0.010
  27. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631.
    View in: PubMed
    Score: 0.010
  28. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.
    View in: PubMed
    Score: 0.009
  29. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
    View in: PubMed
    Score: 0.009
  30. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery. 2018 12; 164(6):1223-1229.
    View in: PubMed
    Score: 0.009
  31. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum. 2018 Oct; 61(10):1146-1155.
    View in: PubMed
    Score: 0.009
  32. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.009
  33. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
    View in: PubMed
    Score: 0.009
  34. Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study. Ann Epidemiol. 2017 11; 27(11):731-738.e1.
    View in: PubMed
    Score: 0.009
  35. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.008
  36. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.008
  37. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
    View in: PubMed
    Score: 0.008
  38. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):918-924.
    View in: PubMed
    Score: 0.008
  39. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26(3):133-7.
    View in: PubMed
    Score: 0.008
  40. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
    View in: PubMed
    Score: 0.007
  41. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):957-66.
    View in: PubMed
    Score: 0.007
  42. Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. Am J Clin Oncol. 2014 Apr; 37(2):122-5.
    View in: PubMed
    Score: 0.007
  43. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.007
  44. Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
    View in: PubMed
    Score: 0.006
  45. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 Apr 01; 18(7):2090-8.
    View in: PubMed
    Score: 0.006
  46. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
    View in: PubMed
    Score: 0.006
  47. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
    View in: PubMed
    Score: 0.005
  48. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer. 2010 Dec; 9(5):290-6.
    View in: PubMed
    Score: 0.005
  49. Predictors of competing mortality in early breast cancer. Cancer. 2010 Dec 01; 116(23):5365-73.
    View in: PubMed
    Score: 0.005
  50. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
    View in: PubMed
    Score: 0.005
  51. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006 Nov 15; 98(22):1647-54.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.